#United States #Class Action #Philadelphia #Berger Montague #Novo Nordisk

Legal Action Against Novo Nordisk A/S

In a significant development for investors holding shares in Novo Nordisk A/S (NYSE: NVO), the law firm Berger Montague PC has initiated an investigation concerning potential violations of federal securities laws. This investigation arises in the wake of a recently filed class action lawsuit against the prominent global pharmaceutical company, headquartered in Denmark.

Background on the Class Action Lawsuit

The issues at hand primarily concern the company's recent performance disclosures. On July 29, 2025, Novo Nordisk announced a downward revision of its sales and profit guidance for the second half of the fiscal year, attributing the shift to several factors: the ongoing popularity of compounded GLP-1 drugs, slower-than-anticipated market growth, and intensified competition affecting its flagship products, Wegovy® and Ozempic®. The market's reaction was swift and severe, resulting in a dramatic plunge in Novo's stock price from $69.00 to $53.94 in a single day—a staggering drop of over 21%.

This substantial loss has raised concerns among investors about the company's transparency and the accuracy of its financial forecasts. As part of the class action lawsuit, individuals who purchased or otherwise acquired Novo securities from May 7 through July 28, 2025, are being encouraged to step forward. Investors are reminded that the deadline to join as lead plaintiff representatives is set for September 30, 2025.

Investor Rights and Actions

For those affected, Berger Montague is actively seeking to represent these investors in the class action suit. The firm is well-versed in securities class action litigation, with a history of representing individual and institutional investors over the past five decades. This experience positions them as a prominent advocate in this complex legal landscape. Investors who endured losses due to the recent stock decline are highly encouraged to understand their rights and consider participating in the legal proceedings.

Berger Montague has expressed their commitment to proactive representation, aiming to hold Novo accountable for any potential misrepresentations that may have misled shareholders during this tumultuous financial period.

Legal Representation Information

If you are an investor in Novo Nordisk and wish to learn more about how you can be involved in this legal action, you should not hesitate to reach out to Berger Montague. Senior Counsel Andrew Abramowitz is available at 215-875-3015 or via email at [email protected], while Caitlin Adorni can be contacted at 267-764-4865 or [email protected].

The Role of Berger Montague

Founded in 1970, Berger Montague has built a reputation as a leading legal firm in the field of securities class action lawsuits. With multiple offices across the United States and Canada, they continue to advocate vigorously for investors' rights, providing essential legal support during turbulent market times.

As this class action lawsuit develops, investors in Novo Nordisk will be watching closely to see how it unfolds and what implications it may have for the pharmaceutical giant’s future. As the legal landscape shifts, maintaining transparency and accountability within the corporate sector remains paramount. Investors are advised to stay informed and proactive about their investments and legal rights.

As the deadline approaches, those with potential claims should act swiftly to ensure their voices are heard in this pivotal legal action.